

Please add the following new claims:

84 22. (New) The method of claim 18, wherein said
protofibril or compound(s) with protofibril forming ability
comprises the following amino acid sequence Lys-Leu-Val-Phe-
Phe-Ala-Glu-Asp-Val (residues 16-24 of SEQ ID NO:1).

23. (New) The method of claim 17 comprising immunization
with A β -Arc as disclosed in SEQ ID NO:1.

REMARKS

1. In response to the objection to claims 4-7, (OA § 5) note that claims 1-7 and 16 were cancelled on October 22, 2001. A courtesy copy of that amendment is enclosed.

2. In response to the restriction, applicants hereby elect group VIII (claims 17-21) without traverse.

3. The Examiner says that the sequence (KLVFFAEDV) of claim 2 is not in the sequence listing and hence, to comply with sequence listing requirements, applicants must (1) provide a substitute sequence listing (paper and CRF) adding that sequence, and (2) amend claim 2 to recite the appropriate sequence identifiers. These requirements are respectfully traversed.

As previously noted, claim 2 has been cancelled. Moreover, this sequence corresponds to residues 16-24 of SEQ ID NO:1, which is already in the sequence listing. Hence, claim 2, even if it had not been cancelled could have been brought into compliance simply by amending that claim; no sequence need be added to the sequence listing.

The Examiner also says that in claims 6 and 8, the sequence identifier is not in proper format. Claim 6 was cancelled October 22, 2001. Claim 8 has been brought into compliance by replacing the hyphen with a colon.

In re Appl. No. 09/899,815
Confirmation No. 9645

4. New claims 22 and 23 correspond to 2 and 6,
respectively.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant

By: 

Iver P. Cooper
Reg. No. 28,005

Enclosure

-Copy of October 22, 2001 Preliminary Amendment

624 Ninth Street, N.W.
Washington, D.C. 20001
Telephone: (202) 628-5197
Facsimile: (202) 737-3528
IPC:nmp\lms

G:\BN\B\Bran\Lannfelt1a\lannfelt1a.ptoelection resptoseq.wpd

In re Appl. No. 09/899,815
Confirmation No. 9645

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the claims:

Claims 22 and 23 have been added.

Claims 8, 17 and 19 have been amended as follows:

8. (Amended) A peptide A β -Arc having the amino acid sequence disclosed in SEQ ID NO-1 comprising a glycine at position 22 instead of glutamic acid compared to wild type A β peptide.

17. (Amended) ~~Method~~ A method for prevention or treatment of ~~AD~~ Alzheimer's Disease (AD), comprising the step: decreasing the formation of A β protofibrils and/or lower meric forms thereof in a subject having, or suspected of having, AD.

19. (Amended) A method according to claim 17, wherein said step is by passive immunisation with antibodies against a non wild-type protofibril or compound(s) with protofibril forming ability, ~~such as A β -Arc.~~